Innate Pharma S.A.'s latest marketcap:
As of 06/06/2025, Innate Pharma S.A.'s market capitalization has reached $201.28 M. According to our data, Innate Pharma S.A. is the 19885th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 201.28 M |
| Revenue (ttm) | 22.94 M |
| Net Income (ttm) | -56,393,477.03 |
| Shares Out | 92.16 M |
| EPS (ttm) | -0.7 |
| Forward PE | 2.60 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/17/2025 |
Innate Pharma S.A.'s yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/06/2025 | €176.57 M | 11.21% |
| 12/31/2024 | €159.94 M | -24.29% |
| 12/29/2023 | €211.24 M | -19.93% |
| 12/30/2022 | €263.84 M | -24.98% |
| 12/31/2021 | €351.67 M | 28.64% |
| 12/31/2020 | €273.37 M |
Company Profile
About Innate Pharma S.A.
Innate Pharma S.A. is a biotechnology company specializing in the development of immunotherapies for cancer patients. Headquartered in Marseille, France, the company operates both domestically and internationally, focusing on innovative treatments to combat various cancers.
Key Products & Pipeline
- Lacutamab (IPH4102) – An anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and refractory Sézary syndrome.
- Monalizumab – An immune checkpoint inhibitor in Phase III trials for advanced solid tumors, including colorectal, lung, and head & neck cancers.
- IPH5201 – A CD39-targeting antibody in Phase II trials to block immunosuppressive pathways.
- IPH5301 – An anti-CD73 antibody aimed at enhancing antitumor immunity.
- IPH6401 & IPH62 – BCMA and B7-H3-targeting NK cell engagers, respectively.
- IPH6101 – A NKp46-based NK cell engager targeting CD123.
- Preclinical Candidates – Including IPH43 (anti-MICA/B ADC), IPH45 (ADC), and IPH67 (undisclosed multi-specific ANKET).
Strategic Collaborations
Innate Pharma has established key partnerships with leading pharmaceutical companies such as:
- AstraZeneca
- Novo Nordisk A/S
- Sanofi
- Orega Biotech
- MedImmune Limited (co-development & licensing agreement)
Founded: 1999
Headquarters: Marseille, France
Frequently Asked Questions
-
What is Innate Pharma S.A.'s (EPA-IPH) current market cap?As of 06/06/2025, Innate Pharma S.A. (including the parent company, if applicable) has an estimated market capitalization of $201.28 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Innate Pharma S.A. (EPA-IPH) rank globally by market cap?Innate Pharma S.A. global market capitalization ranking is approximately 19885 as of 06/06/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.